Statistik Asas
| LEI | 549300SDVB3GP4XDFM60 |
| CIK | 1006281 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Protalix BioTherapeutics, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan senarai kronologi lengkap bagi Pemfailan SEC, tidak termasuk pemfailan pemilikan yang kami sediakan di tempat lain.
| August 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 22, 2025 Protalix BioTherapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33357 65-0643773 (State or other jurisdiction of incorporation) (Com |
|
| August 22, 2025 |
PROSPECTUS SUPPLEMENT Filed Pursuant to Rule 424(b)(5) (to Prospectus dated August 22, 2025) Registration No. |
|
| August 22, 2025 |
[remainder of page intentionally left blank] Exhibit 1.1 August 22, 2025 Protalix BioTherapeutics, Inc. 2 University Plaza, Suite 100 Hackensack, New Jersey 07601 Attention: Eyal Rubin, Chief Financial Officer Dear Mr. Rubin: Reference is made to the At The Market Offering Agreement, dated as of February 27, 2023, as amended on March 17, 2025 (the “ATM Agreement”), between Protalix BioTherapeutics, Inc. (the “Company”) and H.C. Wainwright & |
|
| August 14, 2025 |
As filed with the Securities and Exchange Commission on August 14, 2025 As filed with the Securities and Exchange Commission on August 14, 2025 Registration No. |
|
| August 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to 001-33357 (Commission file number) PROTALIX |
|
| August 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 14, 2025 Protalix BioTherapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33357 65-0643773 (State or other jurisdiction of incorporation) (Com |
|
| August 14, 2025 |
Exhibit 99.1 Protalix BioTherapeutics Reports Second Quarter 2025 Financial and Business Results Company to host conference call and webcast today at 8:30 a.m. EDT CARMIEL, Israel, August 14, 2025 /PRNewswire/ - Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced b |
|
| August 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 1, 2025 Protalix BioTherapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33357 65-0643773 (State or other jurisdiction of incorporation) (Comm |
|
| July 21, 2025 |
Exhibit 99.1 Protalix BioTherapeutics Appoints Gilad Mamlok as its New Senior Vice President and Chief Financial Officer CARMIEL, Israel, July 21, 2025 - Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expr |
|
| July 21, 2025 |
Employment Agreement dated June 13, 2025 Exhibit 10.1 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (this “Agreement”) is made effective as of June 13, 2025 (the “Effective Date”), by and between Protalix Ltd., a company organized under the laws of the State of Israel (the “Company”) and Mr. Gilad Mamlok (the “Employee”) (each of the Company and the Employee shall be referred to herein, as a “Party” and collectively, the “Parties”). WHE |
|
| July 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 21, 2025 (June 13, 2025) Protalix BioTherapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33357 65-0643773 (State or other jurisdiction of incor |
|
| June 26, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 26, 2025 Protalix BioTherapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33357 65-0643773 (State or other jurisdiction of incorporation) (Commi |
|
| May 9, 2025 |
Second Amended and Restated Bylaws of the Company Exhibit 3.7 SECOND AMENDED AND RESTATED BYLAWS OF PROTALIX BIOTHERAPEUTICS, INC. (Adopted May 8, 2025) ARTICLE I OFFICES Section 1.1 Registered Office. The registered office of the corporation in the State of Delaware shall be 1013 Centre Road, Suite 403-B, Wilmington, DE 19805, New Castle County. Section 1.2 Other Offices. The corporation shall also have and maintain an office or principal place |
|
| May 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to 001-33357 (Commission file number) PROTALIX |
|
| May 9, 2025 |
Protalix BioTherapeutics Reports First Quarter 2025 Financial and Business Results Company to host conference call and webcast today at 8:30 a. |
|
| May 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 9, 2025 Protalix BioTherapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33357 65-0643773 (State or other jurisdiction of incorporation) (Commiss |
|
| April 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| April 28, 2025 |
As filed with the Securities and Exchange Commission on April 28, 2025 As filed with the Securities and Exchange Commission on April 28, 2025 Registration No. |
|
| April 28, 2025 |
Exhibit 107 Calculation of Filing Fee Tables FORM S-3 (Form Type) Protalix BioTherapeutics, Inc. |
|
| April 28, 2025 |
Indenture for Senior Securities Exhibit 4.3 Protalix BioTherapeutics, Inc., Issuer AND , Trustee INDENTURE Dated as of , 202 Table of Contents* CROSS-REFERENCE TABLE* Section of Trust Indenture Act of 1939, as amended Section of Indenture 310(a) 7.9 310(b) 7.8 310(c) Inapplicable 311(a) 7.13 311(b) 7.13 311(c) Inapplicable 312(a) 5.01, 5.02(a) 312(b) 5.2(c) 312(c) 5.2(c) 313(a) 5.4(a) 313(b) 5.4(b) 313(c) 5.4(b) 313(d) 5.4(c) 31 |
|
| April 28, 2025 |
Indenture for Subordinated Securities Exhibit 4.4 Protalix BioTherapeutics, Inc., Issuer AND , Trustee INDENTURE Dated as of , 202 Table of Contents* CROSS-REFERENCE TABLE* Section of Trust Indenture Act of 1939, as amended Section of Indenture 310(a) 7.9 310(b) 7.8 310(c) Inapplicable 311(a) 7.13 311(b) 7.13 311(c) Inapplicable 312(a) 5.01, 5.02(a) 312(b) 5.2(c) 312(c) 5.2(c) 313(a) 5.4(a) 313(b) 5.4(b) 313(c) 5.4(b) 313(d) 5.4(c) 31 |
|
| April 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 21, 2025 Protalix BioTherapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33357 65-0643773 (State or other jurisdiction of incorporation) (Comm |
|
| March 17, 2025 |
Exhibit 1.1 March 17, 2025 Protalix BioTherapeutics, Inc. 2 University Plaza, Suite 100 Hackensack, New Jersey 07601 Attention: Eyal Rubin, Chief Financial Officer Dear Mr. Rubin: Reference is made to the At The Market Offering Agreement, dated as of February 27, 2023 (the “ATM Agreement”), between Protalix BioTherapeutics, Inc. (the “Company”) and H.C. Wainwright & Co., LLC (“Wainwright”). This l |
|
| March 17, 2025 |
EXHIBIT 4.4 DESCRIPTION OF CAPITAL STOCK The following summarizes the material terms of the capital stock of Protalix BioTherapeutics, Inc. We are a Delaware corporation. The rights of our stockholders are governed by the Delaware General Corporation Law (the “DGCL”) and by our Certificate of Incorporation, as amended (the “Charter”), and our Amended and Restated Bylaws (the “Bylaws”), which are e |
|
| March 17, 2025 |
Insider Trading and Blackout Policy EXHIBIT 19 Approved as of February 24, 2025 PROTALIX BIOTHERAPEUTICS, INC. INSIDER TRADING AND BLACKOUT POLICY This Insider Trading and Blackout Policy provides guidelines to all personnel (“Restricted Persons”), including employees (both domestic and international), directors and officers, of Protalix BioTherapeutics, Inc. (the “Company”) and its subsidiaries, with respect to transactions in the |
|
| March 17, 2025 |
Subsidiaries of Protalix BioTherapeutics, Inc. EXHIBIT 21.1 Subsidiaries of Protalix BioTherapeutics, Inc. Entity Name State or Country of Organization Protalix Ltd. Israel |
|
| March 17, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 17, 2025 Protalix BioTherapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33357 65-0643773 (State or other jurisdiction of incorporation) (Comm |
|
| March 17, 2025 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 17, 2025 Protalix BioTherapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33357 65-0643773 (State or other jurisdiction of incorporation) (Comm |
|
| March 17, 2025 |
Table of Contents F UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 17, 2025 |
PROSPECTUS SUPPLEMENT Filed Pursuant to Rule 424(b)(5) (to Prospectus dated April 29, 2022) Registration No. |
|
| March 17, 2025 |
Exhibit 99.1 Protalix BioTherapeutics Reports Fiscal Year 2024 Financial and Business Results Company to host conference call and webcast today at 8:30 a.m. EDT CARMIEL, Israel, March 17, 2025 /PRNewswire/ - Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by it |
|
| December 31, 2024 |
Amended and Restated Bylaws of Protalix BioTherapeutics, Inc. Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF PROTALIX BIOTHERAPEUTICS, INC. (Adopted December 27, 2024) ARTICLE I OFFICES Section 1.1 Registered Office. The registered office of the corporation in the State of Delaware shall be 1013 Centre Road, Suite 403-B, Wilmington, DE 19805, New Castle County. Section 1.2 Other Offices. The corporation shall also have and maintain an office or principal place o |
|
| December 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 31, 2024 (December 27, 2024) Protalix BioTherapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33357 65-0643773 (State or other jurisdiction |
|
| December 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 23, 2024 Protalix BioTherapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33357 65-0643773 (State or other jurisdiction of incorporation) (C |
|
| December 23, 2024 |
Protalix BioTherapeutics Issues 2025 Letter to Stockholders Exhibit 99.1 Protalix BioTherapeutics Issues 2025 Letter to Stockholders CARMIEL, Israel, December 23, 2024 /PRNewswire/Protalix BioTherapeutics, Inc. (NYSE American:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell based protein expression system, today announced the |
|
| November 14, 2024 |
Exhibit 99.1 Protalix BioTherapeutics Reports Third Quarter 2024 Financial and Business Results Company to host conference call and webcast today at 8:30 a.m. EST CARMIEL, Israel, November 14, 2024 /PRNewswire/ - Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced |
|
| November 14, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 14, 2024 Protalix BioTherapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33357 65-0643773 (State or other jurisdiction of incorporation) (C |
|
| November 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to 001-33357 (Commission file number) PROT |
|
| October 25, 2024 |
PLX / Protalix BioTherapeutics, Inc. / WHITEBOX ADVISORS LLC Passive Investment SC 13G/A 1 sayw2411140613ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Protalix BioTherapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 74365A309 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appr |
|
| October 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 25, 2024 Protalix BioTherapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33357 65-0643773 (State or other jurisdiction of incorporation) (Co |
|
| October 25, 2024 |
Exhibit 99.1 Protalix BioTherapeutics to Present Phase I PRX-115 Data in Late-Breaking Poster at ACR Convergence 2024 CARMIEL, Israel, October 25, 2024 - Protalix BioTherapeutics, Inc. (NYSE American:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell–based protein expre |
|
| August 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ProCell Or UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to 001-33357 (Commission file number |
|
| August 14, 2024 |
Exhibit 99.1 Protalix BioTherapeutics Reports Second Quarter 2024 Financial and Business Results Company to host conference call and webcast today at 8:30 a.m. EDT CARMIEL, Israel, August 14, 2024 /PRNewswire/ - Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced b |
|
| August 14, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 14, 2024 Protalix BioTherapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33357 65-0643773 (State or other jurisdiction of incorporation) (Com |
|
| July 1, 2024 |
Exhibit 107 Calculation of Filing Fee Tables FORM S-8 (Form Type) Protalix BioTherapeutics, Inc. |
|
| July 1, 2024 |
Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT Under THE SECURITIES ACT OF 1933 Protalix BioTherapeutics, Inc. (Exact name of registrant as specified in its Charter) Delaware 65-0643773 (State or other jurisdiction (I.R.S. Employer of incorporation or organization) Identification Number) 2 University Plaza, Suite 100 Ha |
|
| June 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 27, 2024 Protalix BioTherapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33357 65-0643773 (State or other jurisdiction of incorporation) (Commi |
|
| June 28, 2024 |
Amended and Restated Pro BioTherapeutics, Inc. 2006 Stock Incentive Plan, as amended Exhibit 10.1 PROTALIX BIOTHERAPEUTICS, INC. AMENDED AND RESTATED 2006 STOCK INCENTIVE PLAN, AS AMENDED (JUNE 27, 2024) 1.Purposes of the Plan. The purposes of this Plan are to attract and retain the best available personnel, to provide additional incentives to Employees, Directors and Consultants and to promote the success of the Company’s business. 2.Definitions. The following definitions shall a |
|
| May 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy State |
|
| May 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 10, 2024 Protalix BioTherapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33357 65-0643773 (State or other jurisdiction of incorporation) (Commis |
|
| May 10, 2024 |
Exhibit 99.1 Protalix BioTherapeutics Reports First Quarter 2024 Financial and Business Results Company to host conference call and webcast today at 8:30 a.m. EDT CARMIEL, Israel, May 10, 2024 /PRNewswire/ - Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by it |
|
| May 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ProCell Or UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to 001-33357 (Commission file numbe |
|
| April 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| March 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 14, 2024 Protalix BioTherapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33357 65-0643773 (State or other jurisdiction of incorporation) (Comm |
|
| March 14, 2024 |
Policy Relating to Recovery of Erroneously Awarded Compensation Exhibit 97.1 Approved as of November 14, 2023 PROTALIX BIOTHERAPEUTICS, INC. CLAWBACK POLICY 1.Purpose. The purpose of this Protalix BioTherapeutics, Inc. (the “Company”) Clawback Policy (this “Policy”) is to enable the Company to recover Erroneously Awarded Compensation from Covered Executive Officers in the event that the Company is required to prepare an Accounting Restatement. This Policy is d |
|
| March 14, 2024 |
Exhibit 4.7 DESCRIPTION OF CAPITAL STOCK The following summarizes the material terms of the capital stock of Protalix BioTherapeutics, Inc. We are a Delaware corporation. The rights of our stockholders are governed by the Delaware General Corporation Law (the “DGCL”) and by our Certificate of Incorporation, as amended, and our Bylaws, which are exhibits to our Annual Report on Form 10-K filed with |
|
| March 14, 2024 |
Exhibit 99.1 Protalix BioTherapeutics Reports Fiscal Year 2023 Financial and Business Results Company to host conference call and webcast today at 8:30 a.m. EDT CARMIEL, Israel, March 14, 2024 /PRNewswire/ - Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by it |
|
| March 14, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K FOR ANNUAL AND TRANSITION REPORTS PURSUANT TO SECTIONS 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15( |
|
| January 2, 2024 |
PLX / Protalix BioTherapeutics, Inc. / NACHT MARIUS - SC 13G/A Passive Investment SC 13G/A 1 zk2430712.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 Protalix BioTherapeutics, Inc. (Name of Issuer) Common Stock, Par Value $0.001 per Share (Title of Class of Securities) 74365A309 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the appropri |
|
| December 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 26, 2023 Protalix BioTherapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33357 65-0643773 (State or other jurisdiction of incorporation) (C |
|
| December 26, 2023 |
Protalix BioTherapeutics Issues 2024 Letter to Stockholders Exhibit 99.1 Protalix BioTherapeutics Issues 2024 Letter to Stockholders CARMIEL, Israel, December 26, 2023 /PRNewswire/Protalix BioTherapeutics, Inc. (NYSE American:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell based protein expression system, today announced the |
|
| November 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Or UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to 001-33357 (Commission file number) P |
|
| November 6, 2023 |
Exhibit 99.1 Protalix BioTherapeutics Reports Third Quarter 2023 Financial and Business Results Company to host conference call and webcast today at 8:30 a.m. EST CARMIEL, Israel, November 6, 2023 /PRNewswire/ - Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced b |
|
| November 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 6, 2023 Protalix BioTherapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33357 65-0643773 (State or other jurisdiction of incorporation) (Co |
|
| September 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 12, 2023 Protalix BioTherapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33357 65-0643773 (State or other jurisdiction of incorporation) ( |
|
| September 12, 2023 |
Exhibit 99.1 Protalix BioTherapeutics Appoints Eliot Richard Forster, Ph.D. as Chairman of its Board of Directors Appointment effective as of September 14, 2023; Zeev Bronfeld to retire from the Board of Directors Carmiel, Israel, September 12, 2023 /PRNewswire / Protalix BioTherapeutics, Inc. (NYSE American:PLX), a biopharmaceutical company focused on the development, production and commercializa |
|
| August 11, 2023 |
Exhibit 107 Calculation of Filing Fee Tables FORM S-8 (Form Type) Protalix BioTherapeutics, Inc. |
|
| August 11, 2023 |
Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT Under THE SECURITIES ACT OF 1933 Protalix BioTherapeutics, Inc. (Exact name of registrant as specified in its Charter) Delaware 65-0643773 (State or other jurisdiction (I.R.S. Employer of incorporation or organization) Identification Number) 2 University Plaza, Suite 100 Ha |
|
| August 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Or UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to 001-33357 (Commission file number) PROTAL |
|
| August 7, 2023 |
Amended and Restated Pro BioTherapeutics, Inc. 2006 Stock Incentive Plan, as amended Exhibit 10.1 PROTALIX BIOTHERAPEUTICS, INC. AMENDED AND RESTATED 2006 STOCK INCENTIVE PLAN, AS AMENDED (June 28, 2023) 1.Purposes of the Plan. The purposes of this Plan are to attract and retain the best available personnel, to provide additional incentives to Employees, Directors and Consultants and to promote the success of the Company’s business. 2.Definitions. The following definitions shall a |
|
| August 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 7, 2023 Protalix BioTherapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33357 65-0643773 (State or other jurisdiction of incorporation) (Comm |
|
| August 7, 2023 |
Exhibit 99.1 Protalix BioTherapeutics Reports Second Quarter 2023 Financial and Business Results Company to host conference call and webcast today at 8:30 a.m. EDT CARMIEL, Israel, August 7, 2023 /PRNewswire/ - Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by |
|
| August 7, 2023 |
Fifth Amendment to Certificate of Incorporation of the Company Exhibit 3.6 FIFTH CERTIFICATE OF AMENDMENT TO CERTIFICATE OF INCORPORATION OF PROTALIX BIOTHERAPEUTICS, INC. (Pursuant to Section 242 of the General Corporation Law of the State of Delaware) Protalix BioTherapeutics, Inc., a corporation organized and existing under the laws of the State of Delaware, hereby certifies as follows: 1. The name of the corporation is Protalix BioTherapeutics, Inc. (the |
|
| July 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 13, 2023 Protalix BioTherapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33357 65-0643773 (State or other jurisdiction of incorporation) (Commi |
|
| July 7, 2023 |
Prospectus Supplement No. 1 (To Prospectus Dated April 29, 2020) Filed Pursuant to Rule 424(b)(3) Registration No. 333-237736 Common Stock This Prospectus Supplement supplements, and should be read in conjunction with, our Prospectus included in Registration Statement on Form S-3 (Registration No. 333-237736) dated April 29, 2020 (the “Prospectus”). This Prospectus Supplement must be delivered wit |
|
| June 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 29, 2023 (June 28, 2023) Protalix BioTherapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33357 65-0643773 (State or other jurisdiction of incor |
|
| June 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy State |
|
| May 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 30, 2023 Protalix BioTherapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33357 65-0643773 (State or other jurisdiction of incorporation) (Commis |
|
| May 30, 2023 |
Protalix BioTherapeutics Issues Letter to Stockholders Exhibit 99.1 Protalix BioTherapeutics Issues Letter to Stockholders CARMIEL, Israel, May 30, 2023 /PRNewswire/Protalix BioTherapeutics, Inc. (NYSE American:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today announced the following |
|
| May 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 18, 2023 Protalix BioTherapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33357 65-0643773 (State or other jurisdiction of incorporation) (Commis |
|
| May 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| May 18, 2023 |
Exhibit 99.1 Protalix BioTherapeutics Announces $20 Million Milestone Payment from Chiesi Global Rare Diseases Milestone payment triggered by FDA approval of ELFABRIO® (pegunigalsidase alfa-iwxj) and payable within 30 days of approval CARMIEL, Israel, May 18, 2023 /PRNewswire/ - Protalix BioTherapeutics, Inc. (NYSE American:PLX), a biopharmaceutical company focused on the development, production a |
|
| May 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 10, 2023 Protalix BioTherapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33357 65-0643773 (State or other jurisdiction of incorporation) (Commis |
|
| May 10, 2023 |
Exhibit 99.1 PRESS RELEASE Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce FDA Approval of ELFABRIO® (pegunigalsidase alfa-iwxj) for the Treatment of Fabry Disease - PEGylated enzyme replacement therapy designed to provide long half-life* - BOSTON and CARMIEL, Israel, May 10, 2023 – Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative |
|
| May 5, 2023 |
Exhibit 99.1 PRESS RELEASE Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Authorization of PRX-102 (pegunigalsidase alfa) for the Treatment of Fabry Disease - PEGylated enzyme replacement therapy designed to provide a long half-life - PARMA, Italy, BOSTON and CARMIEL, Israel, May 5, 2023 – Chiesi Global Rare Diseases, a business unit of the Chiesi Group estab |
|
| May 5, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 5, 2023 Protalix BioTherapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33357 65-0643773 (State or other jurisdiction of incorporation) (Commiss |
|
| May 4, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 4, 2023 Protalix BioTherapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33357 65-0643773 (State or other jurisdiction of incorporation) (Commiss |
|
| May 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to 001-33357 (Commission file number) PROTALIX |
|
| May 4, 2023 |
Exhibit 99.1 Protalix BioTherapeutics Reports First Quarter 2023 Financial and Business Results Company to host conference call and webcast today at 8:30 a.m. EDT CARMIEL, Israel, May 4, 2023 /PRNewswire/ - Protalix BioTherapeutics, Inc. (NYSE American:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its |
|
| May 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: x Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy State |
|
| May 1, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) FOR ANNUAL AND TRANSITION REPORTS PURSUANT TO SECTIONS 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT |
|
| February 27, 2023 |
EX-1.1 2 plx-20230227xex1d1.htm EX-1.1 Exhibit 1.1 Protalix BioTherapeutics, Inc. Common Stock ($0.001 par value) AT THE MARKET OFFERING AGREEMENT February 27, 2023 H.C. Wainwright & Co., LLC 430 Park Avenue New York, New York 10022 As Agent Ladies and Gentlemen: Protalix BioTherapeutics, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to |
|
| February 27, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K FOR ANNUAL AND TRANSITION REPORTS PURSUANT TO SECTIONS 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15( |
|
| February 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 27, 2023 Protalix BioTherapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33357 65-0643773 (State or other jurisdiction of incorporation) (C |
|
| February 27, 2023 |
Exhibit 99.1 Protalix BioTherapeutics Reports Fiscal Year 2022 Financial and Business Results Company to host conference call and webcast today at 8:30 a.m. EST CARMIEL, Israel, February 27, 2023 /PRNewswire/ - Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins p |
|
| February 27, 2023 |
Exhibit 4.7 DESCRIPTION OF CAPITAL STOCK The following summarizes the material terms of the capital stock of Protalix BioTherapeutics, Inc. We are a Delaware corporation. The rights of our stockholders are governed by the Delaware General Corporation Law (the “DGCL”) and by our Certificate of Incorporation, as amended, and our Bylaws, which are exhibits to our Annual Report on Form 10-K filed with |
|
| February 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 27, 2023 Protalix BioTherapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33357 65-0643773 (State or other jurisdiction of incorporation) (C |
|
| February 27, 2023 |
Prospectus Supplement Filed Pursuant to Rule 424(b)(5) (to Prospectus dated April 29, 2022) Registration No. |
|
| February 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 24, 2023 Protalix BioTherapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33357 65-0643773 (State or other jurisdiction of incorporation) (C |
|
| February 24, 2023 |
Exhibit 99.1 Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for Pegunigalsidase Alfa for Treatment of Fabry Disease - European Commission decision anticipated in beginning of May 2023 - PARMA/BOSTON and CARMIEL, Israel, February 24, 2023 – Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutio |
|
| January 3, 2023 |
PLX / Protalix BioTherapeutics, Inc. / NACHT MARIUS - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 Protalix BioTherapeutics, Inc. (Name of Issuer) Common Stock, Par Value $0.001 per Share (Title of Class of Securities) 74365A309 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule purs |
|
| January 3, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 3, 2023 Protalix BioTherapeutics, Inc. (Exact name of registrant as specified in its charter) ? ? ? ? ? ? Delaware 001-33357 65-0643773 (State or other jurisdiction of inc |
|
| January 3, 2023 |
Protalix BioTherapeutics Issues 2023 Letter to Stockholders Exhibit 99.1 ? Protalix BioTherapeutics Issues 2023 Letter to Stockholders CARMIEL, Israel, January 3, 2023 /PRNewswire/Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx? plant cell based protein expression system, today ann |
|
| December 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 27, 2022 Protalix BioTherapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33357 65-0643773 (State or other jurisdiction of incorporation) (C |
|
| December 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 21, 2022 Protalix BioTherapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33357 65-0643773 (State or other jurisdiction of incorporation) (C |
|
| December 21, 2022 |
Exhibit 99.1 ? Protalix BioTherapeutics to Delist its Common Stock from the Tel Aviv Stock Exchange The Company?s Common Stock will continue to trade on the NYSE American CARMIEL, Israel, December 21, 2022 /PRNewswire/Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic pro |
|
| November 14, 2022 |
Exhibit 99.2 Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Resubmission of Biologics License Application to U.S. Food and Drug Administration for Pegunigalsidase Alfa for the Treatment of Fabry Disease CARMIEL, Israel and BOSTON, November 14, 2022 /PRNewswire/Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development, p |
|
| November 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 9, 2022 Protalix BioTherapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33357 65-0643773 (State or other jurisdiction of incorporation) (Co |
|
| November 14, 2022 |
Exhibit 99.1 Protalix BioTherapeutics Reports Third Quarter 2022 Financial and Business Results Company to host conference call and webcast today at 8:30 a.m. EST CARMIEL, Israel, November 14, 2022 - Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by |
|
| November 14, 2022 |
Exhibit 10.1 CONFIDENTIAL EXECUTION VERSION Certain confidential portions of this exhibit have been omitted and replaced with “[***]”. Such identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. FILL/FINISH AGREEMENT by and between CHIESI FARMACEUTICI S.p.A. and PROTALIX LTD. FILL/FINISH AGRE |
|
| November 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to 001-33357 (Commission file number) PROT |
|
| November 14, 2022 |
Letter Agreement dated August 29, 2022 from Chiesi Farmaceutici S.p.A to Protalix Ltd. Exhibit 10.2 CONFIDENTIAL EXECUTION VERSION Certain confidential portions of this exhibit have been omitted and replaced with “[***]”. Such identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Via Palermo 26/A, Parma, 43122 Italy August 29, 2022 Dror Bashan President and Chief Executive Off |
|
| September 1, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 29, 2022 Protalix BioTherapeutics, Inc. (Exact name of registrant as specified in its charter) ? ? ? ? ? ? Delaware 001-33357 65-0643773 (State or other jurisdiction of inc |
|
| August 15, 2022 |
Fourth Amendment to Certificate of Incorporation of the Company EXHIBIT 3.5 ? ? FOURTH CERTIFICATE OF AMENDMENT TO CERTIFICATE OF INCORPORATION OF PROTALIX BIOTHERAPEUTICS, INC. (Pursuant to Section 242 of the General Corporation Law of the State of Delaware) Protalix BioTherapeutics, Inc., a corporation organized and existing under the laws of the State of Delaware, hereby certifies as follows: 1. The name of the corporation is Protalix BioTherapeutics, Inc. |
|
| August 15, 2022 |
Exhibit 99.1 Protalix BioTherapeutics Reports Second Quarter 2022 Financial and Business Results Company to host conference call and webcast today at 8:30 a.m. EDT CARMIEL, Israel, August 15, 2022 - Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by i |
|
| August 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? ? ? ? ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? ? FORM 10-Q ? ? (Mark One) ? ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? For the quarterly period ended June 30, 2022 ? OR ? ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? For the transition period from to ? 001-33357 (C |
|
| August 15, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 15, 2022 Protalix BioTherapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33357 65-0643773 (State or other jurisdiction of incorporation) (Com |
|
| July 14, 2022 |
Exhibit 107 Calculation of Filing Fee Tables FORM S-8 (Form Type) Protalix BioTherapeutics, Inc. |
|
| July 14, 2022 |
Amended and Restated Pro BioTherapeutics, Inc. 2006 Stock Incentive Plan, as amended Exhibit 4.1 PROTALIX BIOTHERAPEUTICS, INC. AMENDED AND RESTATED 2006 STOCK INCENTIVE PLAN, AS AMENDED (June 30, 2022) 1.????????????Purposes of the Plan. The purposes of this Plan are to attract and retain the best available personnel, to provide additional incentives to Employees, Directors and Consultants and to promote the success of the Company?s business. 2.????????????Definitions. The follow |
|
| July 14, 2022 |
Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT Under THE SECURITIES ACT OF 1933 Protalix BioTherapeutics, Inc. (Exact name of registrant as specified in its Charter) Delaware 65-0643773 (State or other jurisdiction (I.R.S. Employer of incorporation or organization) Identification Number) 2 University Plaza, Suite 100 Ha |
|
| June 30, 2022 |
Protalix BioTherapeutics Appoints Shmuel “Muli” Ben Zvi, Ph.D. to its Board of Directors Exhibit 99.1 ? Protalix BioTherapeutics Appoints Shmuel ?Muli? Ben Zvi, Ph.D. to its Board of Directors Carmiel, Israel, June 30, 2022 /PRNewswire / Protalix BioTherapeutics, Inc. (NYSE American:PLX, TASE:PLX), announced today that the Company?s Board of Directors has appointed Shmuel ?Muli? Ben Zvi, Ph.D. to serve on the Company?s Board of Directors. In addition to Dr. Ben Zvi?s appointment as an |
|
| June 30, 2022 |
? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 29, 2022 Protalix BioTherapeutics, Inc. (Exact name of registrant as specified in its charter) ? ? ? ? ? ? Delaware 001-33357 65-0643773 (State or other jurisdiction of incor |
|
| June 29, 2022 |
June 29, 2022 U.S. Securities and Exchange Commission Division of Corporate Finance Office of Life Sciences Mail Stop 4720 100 F Street, N.E. Washington, D.C. 20549 Re: Protalix BioTherapeutics, Inc. Form 10-K for the Fiscal Year Ended December 31, 2021 Filed March 31, 2022 File No. 001-33357 Ladies and Gentlemen: Transmitted herewith is the response of Protalix BioTherapeutics, Inc. (the “Company |
|
| June 16, 2022 |
DEFA14A 1 tm2218595d1defa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by R |
|
| June 9, 2022 |
PLX / Protalix BioTherapeutics, Inc. / WHITEBOX ADVISORS LLC - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| May 26, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 26, 2022 Protalix BioTherapeutics, Inc. (Exact name of registrant as specified in its charter) ? ? ? ? ? ? Delaware 001-33357 65-0643773 (State or other jurisdiction of incorp |
|
| May 26, 2022 |
Exhibit 99.1 ? Protalix BioTherapeutics Announces Poster Presentations at the 2022 Program: 7th Update on Fabry Disease CARMIEL, Israel, May 26, 2022 - Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx? plant cell-based prot |
|
| May 16, 2022 |
Exhibit 99.1 ? Protalix BioTherapeutics Reports First Quarter 2022 Financial and Business Results Company to host conference call and webcast today at 8:30 a.m. EDT CARMIEL, Israel, May 16, 2022 - Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its |
|
| May 16, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 16, 2022 Protalix BioTherapeutics, Inc. (Exact name of registrant as specified in its charter) ? ? ? ? ? ? Delaware 001-33357 65-0643773 (State or other jurisdiction of incorp |
|
| May 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? ? ? ? fFFAS ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? ? FORM 10-Q ? ? (Mark One) ? ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? For the quarterly period ended March 31, 2022 ? OR ? ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? For the transition period from to ? 001-333 |
|
| May 2, 2022 |
Letter Amendment dated May 2, 2022 Exhibit 1.1 ? ? May 2, 2022 ? Protalix BioTherapeutics 2 University Plaza, Suite 100 Hackensack, New Jersey 07601 Attention: Eyal Rubin, Chief Financial Officer ? Dear Mr. Rubin: ? Reference is made to the At The Market Offering Agreement, dated as of July 2, 2021 (the ?ATM Agreement?), between Protalix BioTherapeutics (the ?Company?) and H.C. Wainwright & Co., LLC (the ?Wainwright?). This letter |
|
| May 2, 2022 |
Prospectus Supplement Filed Pursuant to Rule 424(b)(5) (to Prospectus dated April 29, 2022) Registration No. |
|
| May 2, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 2, 2022 Protalix BioTherapeutics, Inc. (Exact name of registrant as specified in its charter) ? ? ? ? ? ? Delaware 001-33357 65-0643773 (State or other jurisdiction of incorpo |
|
| April 29, 2022 |
DEF 14A 1 tm2213754-1def14a.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Ru |
|
| April 27, 2022 |
CORRESP 1 filename1.htm April 27, 2022 VIA EDGAR Jessica Ansart Office of Life Sciences U.S. Securities and Exchange Commission Division of Corporation Finance Mail Stop 4720 100 F Street, N.E. Washington, D.C. 20549 Re: Protalix BioTherapeutics, Inc. Registration Statement on Form S-3 Filed April 20, 2022 File No. 333-264394 Dear Ms. Ansart: We refer to the registration statement on Form S-3 (Fil |
|
| April 20, 2022 |
Indenture for Senior Securities Exhibit 4.3 Protalix BioTherapeutics, Inc., Issuer AND , Trustee INDENTURE Dated as of , 202 Table of Contents* CROSS-REFERENCE TABLE* Section of Trust Indenture Act of 1939, as amended Section of Indenture 310(a) 7.9 310(b) 7.8 310(c) Inapplicable 311(a) 7.13 311(b) 7.13 311(c) Inapplicable 312(a) 5.01, 5.02(a) 312(b) 5.2(c) 312(c) 5.2(c) 313(a) 5.4(a) 313(b) 5.4(b) 313(c) 5.4(b) 313(d) 5.4(c) 31 |
|
| April 20, 2022 |
Exhibit 107 Calculation of Filing Fee Tables FORM S-3 (Form Type) Protalix BioTherapeutics, Inc. |
|
| April 20, 2022 |
As filed with the Securities and Exchange Commission on April 20, 2022 As filed with the Securities and Exchange Commission on April 20, 2022 Registration No. |
|
| April 20, 2022 |
Indenture for Subordinated Securities Exhibit 4.4 Protalix BioTherapeutics, Inc., Issuer AND , Trustee INDENTURE Dated as of , 202 Table of Contents* CROSS-REFERENCE TABLE* Section of Trust Indenture Act of 1939, as amended Section of Indenture 310(a) 7.9 310(b) 7.8 310(c) Inapplicable 311(a) 7.13 311(b) 7.13 311(c) Inapplicable 312(a) 5.01, 5.02(a) 312(b) 5.2(c) 312(c) 5.2(c) 313(a) 5.4(a) 313(b) 5.4(b) 313(c) 5.4(b) 313(d) 5.4(c) 31 |
|
| April 14, 2022 |
PRE 14A 1 tm2212755d1pre14a.htm PRE 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: x Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Ru |
|
| April 4, 2022 |
Exhibit 99.1 Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Topline Results from the 24-Month Phase III BALANCE Clinical Trial of PRX-102 for the Treatment of Fabry Disease PRX-102 successfully met the primary endpoint on kidney function in active control, non-inferiority study vs. agalsidase beta Topline results demonstrated a favorable tolerability and immunogenicity profile |
|
| April 4, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 4, 2022 Protalix BioTherapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33357 65-0643773 (State or other jurisdiction of incorporation) (Commi |
|
| March 31, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 31, 2022 Protalix BioTherapeutics, Inc. (Exact name of registrant as specified in its charter) ? ? ? ? ? ? Delaware 001-33357 65-0643773 (State or other jurisdiction of inco |
|
| March 31, 2022 |
Table of Contents gbEnterF ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 31, 2022 |
Exhibit 99.1 Protalix BioTherapeutics Reports Fiscal Year 2021 Financial and Business Results Company to host conference call and webcast at 8:30 a.m. EDT CARMIEL, Israel, March 31, 2022 - Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprie |
|
| February 24, 2022 |
Exhibit 99.1 ? ? ? Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce the Submission of a Marketing Authorization Application to the European Medicines Agency for PRX-102 for the Treatment of Fabry Disease CARMIEL, Israel and BOSTON, February 24, 2022 - Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development, production a |
|
| February 24, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 24, 2022 Protalix BioTherapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33357 65-0643773 (State or other jurisdiction of incorporation) (C |
|
| February 14, 2022 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Protalix BioTherapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 74365A309 (CUSIP Number) December 31, 2021** (Date of event which requires filing of this statement) Check the appropriate box to designate the ru |
|
| February 11, 2022 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Protalix BioTherapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 74365A309 (CUSIP Number) December 31, 2021 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule |
|
| January 31, 2022 |
PLX / Protalix BioTherapeutics, Inc. / NACHT MARIUS - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 Protalix BioTherapeutics, Inc. (Name of Issuer) Common Stock, Par Value $0.001 per Share (Title of Class of Securities) 74365A309 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule purs |
|
| December 22, 2021 |
Protalix BioTherapeutics Issues 2021 Letter to Stockholders ?Exhibit 99.1 ? ? ? ? ? Protalix BioTherapeutics Issues 2021 Letter to Stockholders CARMIEL, Israel, December 22, 2021 /PRNewswire/ - Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx? plant cell-based protein expression sys |
|
| December 22, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 22, 2021 Protalix BioTherapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33357 65-0643773 (State or other jurisdiction of incorporation) (C |
|
| November 24, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 24, 2021 Protalix BioTherapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33357 65-0643773 (State or other jurisdiction of incorporation) (C |
|
| November 15, 2021 |
? ? ? Exhibit 99.1 ? ? ? ? ? BioTherapeutics Reports Third Quarter 2021 Financial Results and Provides Financial and Business Update Company to host conference call and webcast today at 8:30 a.m. EST CARMIEL, Israel, November 15, 2021 /PRNewswire/ - Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development, production and commercializatio |
|
| November 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? ? ? ? fFFAS ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? ? FORM 10-Q ? ? (Mark One) ? ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? For the quarterly period ended September 30, 2021 ? OR ? ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? For the transition period from to ? 001 |
|
| November 15, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 15, 2021 Protalix BioTherapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33357 65-0643773 (State or other jurisdiction of incorporation) (C |
|
| November 9, 2021 |
DEFA14A 1 tm2132349d1defa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by R |
|
| October 12, 2021 |
Financial Statements and Exhibits, Other Events ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 12, 2021 (October 11, 2021) Protalix BioTherapeutics, Inc. (Exact name of registrant as specified in its charter) ? ? ? ? ? ? Delaware 001-33357 65-0643773 (State or other |
|
| October 12, 2021 |
?Exhibit 99.1 ? ? ? ? Protalix Biotherapeutics and Chiesi Global Rare Diseases Provide Regulatory Update on PRX-102 for the Treatment of Fabry Disease CARMIEL, Israel and BOSTON, October 11, 2021 /PRNewswire/ - Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins p |
|
| September 30, 2021 |
? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? SCHEDULE 14A ? Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 ? Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? ? Preliminary Proxy Statement ? ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? ? Definiti |
|
| September 17, 2021 |
? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? SCHEDULE 14A ? Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 ? Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? ? Preliminary Proxy Statement ? ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? ? Definiti |
|
| August 26, 2021 |
Protalix BioTherapeutics Announces Closing of Private Note Exchange ? Exhibit 99.1 ? ? Protalix BioTherapeutics Announces Closing of Private Note Exchange CARMIEL, Israel, August 26, 2021 /PRNewswire/Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx? plant cell-based protein expression syste |
|
| August 26, 2021 |
? Exhibit 10.2 ? Dated August 24, 2021 BETWEEN ? ? PROTALIX LTD. ? as the Company ? ? AND ? ? ALTSHULER SHAHAM TRUSTS LTD. ? as Security Trustee ? ? ? ? ? 2021 SECURITY AGREEMENT/DEBENTURE UNLIMITED IN AMOUNT ? ? ? ? ? THIS 2021 SECURITY AGREEMENT/DEBENTURE is made on the 24 day of August 2021 (the ?2021 Floating and Fixed Charge Agreement?) Between: (1) PROTALIX LTD., a private limited company du |
|
| August 26, 2021 |
Exhibit 4.2 Execution Version PROTALIX BIOTHERAPEUTICS, INC. AS ISSUER AND EACH OF THE GUARANTORS PARTY HERETO 7.50% SENIOR SECURED CONVERTIBLE NOTES DUE 2024 INDENTURE DATED AS OF AUGUST 24, 2021 THE BANK OF NEW YORK MELLON TRUST COMPANY, N.A. AS TRUSTEE WILMINGTON SAVINGS FUND SOCIETY, FSB ? AS COLLATERAL AGENT ? ? ? ?? ? ? Table of Contents Article 1 DEFINITIONS AND INCORPORATION BY REFERENCE?1 |
|
| August 26, 2021 |
? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 26, 2021 (August 24, 2021) Protalix BioTherapeutics, Inc. (Exact name of registrant as specified in its charter) ? ? ? ? ? ? Delaware 001-33357 65-0643773 (State or other j |
|
| August 26, 2021 |
Exhibit 4.1 ? Execution Version ? THIRD Supplemental Indenture ? by and among ? PROTALIX BIOTHERAPEUTICS, INC., as Issuer, AND EACH OF THE GUARANTORS PARTY HERETO, ? and ? The Bank of New York Mellon Trust CoMPANY, N.A., as Trustee, and ? wilmington savings fund society, fsb, as Collateral Agent ? dated as of August 24, 2021 to the Indenture, dated as of December 7, 2016, as supplemented by the Fi |
|
| August 26, 2021 |
Exhibit 4.3 THIS IS A GLOBAL NOTE WITHIN THE MEANING OF THE INDENTURE HEREINAFTER REFERRED TO AND IS REGISTERED IN THE NAME OF THE DEPOSITARY OR A NOMINEE OF THE DEPOSITARY, WHICH MAY BE TREATED BY THE COMPANY, THE TRUSTEE AND ANY AGENT THEREOF AS OWNER AND HOLDER OF THIS NOTE FOR ALL PURPOSES. UNLESS THIS CERTIFICATE IS PRESENTED BY AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITORY TRUST COMPANY TO |
|
| August 26, 2021 |
Exhibit 10.1 ? EXECUTION VERSION AMENDED AND RESTATED SECURITY AGREEMENT dated as of August 24, 2021 among PROTALIX BIOTHERAPEUTICS, INC., as Issuer THE GUARANTORS PARTY HERETO, WILMINGTON SAVINGS FUND SOCIETY, FSB, as Collateral Agent THE BANK OF NEW YORK MELLON TRUST COMPANY, N.A., as 2021 Notes Trustee and THE BANK OF NEW YORK MELLON TRUST COMPANY, N.A., as 2024 Notes Trustee ? ? ? ? Table of C |
|
| August 16, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 16, 2021 Protalix BioTherapeutics, Inc. (Exact name of registrant as specified in its charter) ? ? ? ? ? ? Delaware 001-33357 65-0643773 (State or other jurisdiction of inc |
|
| August 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? ? fFFAS ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? ? FORM 10-Q ? ? (Mark One) ? ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? For the quarterly period ended June 30, 2021 ? OR ? ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? For the transition period from to ? 001-33357 (C |
|
| August 16, 2021 |
Exhibit 99.1 ? ? Protalix BioTherapeutics Reports Second Quarter 2021 Financial Results and Financial and Business Update ? CARMIEL, Israel, August 16, 2021 ? Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx? plant cell-b |
|
| August 13, 2021 |
? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 13, 2021 (August 12, 2021) Protalix BioTherapeutics, Inc. (Exact name of registrant as specified in its charter) ? ? ? ? ? ? Delaware 001-33357 65-0643773 (State or other j |
|
| August 13, 2021 |
Exhibit 10.1 ? Execution Version ? ? EXCHANGE AGREEMENT by and among Protalix BioTherapeutics, Inc. and the Parties Signatory Hereto Dated as of August 12, 2021 ? ? ? ? EXCHANGE AGREEMENT dated as of August 12, 2021 (this ?Agreement?), by and among Protalix BioTherapeutics, Inc., a Delaware corporation (the ?Company?), and the parties signatory hereto (each, a ?Purchaser,? and collectively, the ?P |
|
| August 13, 2021 |
Protalix BioTherapeutics Announces Private Note Exchange ? Exhibit 99.1 ? ? Protalix BioTherapeutics Announces Private Note Exchange CARMIEL, Israel, August 13, 2021 /PRNewswire/Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx? plant cell-based protein expression system, today an |
|
| July 30, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Protalix BioTherapeutics Inc (Name of Issuer) Common Stock (Title of Class of Securities) 74365A309 (CUSIP Number) 06/30/2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this S |
|
| July 7, 2021 |
Submission of Matters to a Vote of Security Holders ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 7, 2021 Protalix BioTherapeutics, Inc. (Exact name of registrant as specified in its charter) ? ? ? ? ? ? Delaware 001-33357 65-0643773 (State or other jurisdiction of incorp |
|
| July 2, 2021 |
Prospectus Supplement Filed Pursuant to Rule 424(b)(5) (to Prospectus dated April 12, 2019) Registration No. |
|
| July 2, 2021 |
The date of this Supplement No. 1 is July 2, 2021 Supplement No. 1 dated July 2, 2021 to Filed Pursuant to Rule 424(b)(5) Prospectus Supplement dated October 1, 2020 Registration No. 333-230604 (To Prospectus dated April 12, 2019) This Supplement No. 1 to Prospectus Supplement supplements and amends the Prospectus Supplement dated October 1, 2020 (the ?ATM Prospectus Supplement?) filed by us. This Supplement No. 1 to the ATM Prospectus Supplement |
|
| July 2, 2021 |
Exhibit 1.1 Protalix BioTherapeutics, Inc. Common Stock ($0.001 par value) AT THE MARKET OFFERING AGREEMENT July 2, 2021 H.C. Wainwright & Co., LLC 430 Park Avenue New York, New York 10022 As Agent Ladies and Gentlemen: Protalix BioTherapeutics, Inc., a Delaware corporation (the ?Company?), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time to or throu |
|
| July 2, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 2, 2021 Protalix BioTherapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33357 65-0643773 (State or other jurisdiction of incorporation) (Commis |
|
| June 30, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 30, 2021 Protalix BioTherapeutics, Inc. (Exact name of registrant as specified in its charter) ? ? ? ? ? ? Delaware 001-33357 65-0643773 (State or other jurisdiction of incor |
|
| June 15, 2021 |
PLX / Protalix BioTherapeutics, Inc. / Dexcel Pharma Technologies Ltd. - SC 13G/A Passive Investment SC 13G/A 1 tm2119639d1sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Protalix BioTherapeutics, Inc. (Name of Issuer) Common shares, par value $0.001 per share (Title of Class of Securities) 74365A309 (CUSIP Number) June 14, 2021 (Date of Event Which Requires Filing of this Stateme |
|
| June 4, 2021 |
? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? SCHEDULE 14A ? Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 ? Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? ? Preliminary Proxy Statement ? ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? ? Definiti |
|
| June 2, 2021 |
? Exhibit 99.1 ? ? ? Protalix Biotherapeutics and Chiesi Global Rare Diseases Provide Update Regarding Clinical Development of PRX-102 for Treatment of Fabry Disease Companies Announce Topline Results from Interim Analysis of Phase III BALANCE Clinical Trial Protalix management to host conference call and live webcast today at 8:30 am EDT CARMIEL, Israel and BOSTON, June 2, 2021 - Protalix BioTher |
|
| June 2, 2021 |
Financial Statements and Exhibits, Other Events ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 2, 2021 Protalix BioTherapeutics, Inc. (Exact name of registrant as specified in its charter) ? ? ? ? ? ? Delaware 001-33357 65-0643773 (State or other jurisdiction of incorp |
|
| May 14, 2021 |
Binding Term Sheet between Protalix Ltd. and Chiesi Farmaceutici S.p.A. Exhibit 10.3 ? [***] Represents material that has been omitted and will be filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment under Rule 24b-2 of the Securities and Exchange Act of 1934, as amended. ? Binding Term Sheet between Chiesi Farmaceutici S.p.A. (?Chiesi?) and Protalix Ltd. (?Protalix?) for amending the U.S. and Ex-U.S. Exclusive |
|
| May 14, 2021 |
EX-99.1 2 plx-20210514xex99d1.htm EX-99.1 Exhibit 99.1 Protalix BioTherapeutics Reports First Quarter 2021 Financial Results and Business Update Management to host conference call and live webcast today at 8:30 am EDT CARMIEL, Israel, May 14, 2021 /PRNewswire/ - Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and c |
|
| May 14, 2021 |
fFFAS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents fFFAS ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| May 14, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 14, 2021 Protalix BioTherapeutics, Inc. (Exact name of registrant as specified in its charter) ? ? ? ? ? ? Delaware 001-33357 65-0643773 (State or other jurisdiction of incorp |
|
| May 14, 2021 |
Exhibit 10.2 [***] Represents material that has been omitted and will be filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment under Rule 24b-2 of the Securities and Exchange Act of 1934, as amended. TECHNOLOGY TRANSFER AND SUPPLY AGREEMENT This TECHNOLOGY TRANSFER AND SUPPLY AGREEMENT (this ?AGREEMENT?) is made as of , 2013 by and between PR |
|
| May 14, 2021 |
Exhibit 10.1 Execution Version [***] Represents material that has been omitted and will be filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment under Rule 24b-2 of the Securities and Exchange Act of 1934, as amended. AGREEMENT This Agreement is made and entered into on this 17 day of June, 2013 Between PROTALIX LTD. a company duly incorporat |
|
| April 30, 2021 |
? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? FORM 10-K/A (Amendment No. 1) ? ? FOR ANNUAL AND TRANSITION REPORTS PURSUANT TO SECTIONS 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? ? ? ? ? For the fiscal year ended December 31, 2020 ? OR ? TRANSITION REPORT PURSU |
|
| April 28, 2021 |
Financial Statements and Exhibits, Other Events ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 28, 2021 Protalix BioTherapeutics, Inc. (Exact name of registrant as specified in its charter) ? ? ? ? ? ? Delaware 001-33357 65-0643773 (State or other jurisdiction of inco |
|
| April 28, 2021 |
Exhibit 99.1 ? ? ? Protalix BioTherapeutics and Chiesi Global Rare Diseases Receive Complete Response Letter for Pegunigalsidase Alfa from FDA ? CARMIEL, Israel and BOSTON, Mass. ? April 28, 2021 ? Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by it |
|
| March 30, 2021 |
Exhibit 99.1 Protalix BioTherapeutics Reports Fiscal Year 2020 Financial and Business Results In February 2021, announced positive top-line results from the Company’s phase III BRIGHT clinical trial In December 2020, announced positive final results from the Company’s phase III BRIDGE clinical trial Successfully raised approximately $40 million in gross proceeds in an equity offering led by BofA S |
|
| March 30, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 30, 2021 Protalix BioTherapeutics, Inc. (Exact name of registrant as specified in its charter) ? ? ? ? ? ? Delaware 001-33357 65-0643773 (State or other jurisdiction of inco |
|
| March 30, 2021 |
Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| February 23, 2021 |
? ? Exhibit 99.1 ? ? ? Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Positive Topline Results from BRIGHT Phase III Open-Label, Switch-Over Clinical Trial Evaluating Pegunigalsidase Alfa 2 mg/kg every Four Weeks for Treatment of Fabry Disease ? Study achieved key objectives for safety, efficacy and pharmacokinetics After completion of the study, all patients enrolled in an exte |
|
| February 23, 2021 |
Financial Statements and Exhibits, Other Events ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 23, 2021 Protalix BioTherapeutics, Inc. (Exact name of registrant as specified in its charter) ? Delaware 001-33357 65-0643773 (State or other jurisdiction of incorporati |
|
| February 16, 2021 |
Protalix BioTherapeutics Announces Pricing of its Upsized Public Offering of Common Stock Exhibit 99.2 Protalix BioTherapeutics Announces Pricing of its Upsized Public Offering of Common Stock CARMIEL, Israel, February 11, 2021 /PR Newswire/ - Protalix BioTherapeutics, Inc. (NYSE American: PLX, TASE: PLX) (the ?Company?), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx? pl |
|
| February 16, 2021 |
Protalix BioTherapeutics Announces Proposed Public Offering of Common Stock Exhibit 99.1 Protalix BioTherapeutics Announces Proposed Public Offering of Common Stock CARMIEL, Israel, February 11, 2021 /PR Newswire/ - Protalix BioTherapeutics, Inc. (NYSE American: PLX, TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein express |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Protalix BioTherapeutics, Inc. (Name of Issuer) Common shares, par value $0.001 per share (Title of Class of Securities) 74365A309 (CUSIP Number) February 12, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to desig |
|
| February 16, 2021 |
Filed pursuant to Rule 424(b)(5) Registration Statement No. 333-230604 P R O S P E C T U S S U P P L E M E N T (to Prospectus dated March 29, 2019) 7,608,695 Shares Common Stock We are selling 7,608,695 shares of our common stock. Our common stock is listed on the NYSE American LLC (“NYSE American”) under the symbol “PLX” and on the Tel Aviv Stock Exchange (“TASE”) under the symbol “PLX.” On Febru |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 16, 2021 (February 11, 2021) Protalix BioTherapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33357 65-0643773 (State or other jurisdiction |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5)* Protalix Biotherapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 74365A309 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to design |
|
| February 16, 2021 |
Underwriting Agreement, dated February 11, 2021, between the Company and BofA Securities, Inc. Exhibit 1.1 PROTALIX BIOTHERAPEUTICS, INC. (a Delaware corporation) 7,608,695 Shares of Common Stock UNDERWRITING AGREEMENT Dated: February 11, 2021 EXECUTION VERSION Protalix BioTherapeutics, Inc. (a Delaware corporation) 7,608,695 Shares of Common Stock UNDERWRITING AGREEMENT February 11, 2021 BofA Securities, Inc. as Representative of the several Underwriters c/o BofA Securities, Inc. One Bryan |
|
| February 12, 2021 |
SC 13G 1 burr20210205sc13g.htm SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Protalix BioTherapeutics Inc (Name of Issuer) Common Stock (Title of Class of Securities) 74365A309 (CUSIP Number) 12/04/2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to |
|
| February 11, 2021 |
Subject to Completion Preliminary Prospectus dated February 11, 2021 The information in this prospectus is not complete and may be changed. We may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and it is not soliciting an offer to buy these securities in any state where the offer or sale is not permitted. Filed pursuant to Rule 424(b) |
|
| February 9, 2021 |
Protalix BioTherapeutics, Inc. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Protalix BioTherapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 74365A309 (CUSIP Number) December 31, 2020 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule |
|
| February 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 Protalix BioTherapeutics, Inc. (Name of Issuer) Common Stock, Par Value $0.001 per Share (Title of Class of Securities) 74365A309 (CUSIP Number) December 31, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule purs |
|
| February 8, 2021 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 (AMENDMENT NO. 3)* Protalix BioTherapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 74365A-30-9 (CUSIP Number) December 31, 2020 (Date of Event Wh |
|
| February 8, 2021 |
EXHIBIT 1 AGREEMENT AS TO JOINT FILING OF SCHEDULE 13G Each of the undersigned hereby affirms that it is individually eligible to use Schedule 13G, and agrees that this Schedule 13G is filed on its behalf. |
|
| December 30, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 30, 2020 Protalix BioTherapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33357 65-0643773 (State or other jurisdiction of incorporation) (C |
|
| December 30, 2020 |
Exhibit 99.1 December 30, 2020 Dear Protalix shareholders, As we look forward to 2021 with great anticipation, I want to take a moment to reflect on our transformational accomplishments this past year, which has been unlike any we could have imagined. Together with our development and commercialization partner, Chiesi Global Rare Diseases, we submitted to the U.S. Food and Drug Administration (FDA |
|
| November 24, 2020 |
PLX / Protalix BioTherapeutics, Inc. / NACHT MARIUS - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Protalix Bio Therapeutics Inc. (Name of Issuer) Common Stock, par value US$ 0.001 per Share (Title of Class of Securities) 74365A309 (CUSIP Number) March 18, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursua |
|
| October 29, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to 001-33357 (Commission |
|
| October 29, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 29, 2020 Protalix BioTherapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33357 65-0643773 (State or other jurisdiction of incorporation) (Co |
|
| October 29, 2020 |
Exhibit 99.1 Protalix BioTherapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update Announced FDA acceptance of BLA filing of PRX-102 for the treatment of Fabry disease Top-line data from the BRIGHT study expected by end of first quarter, 2021 Management to host conference call and live webcast today, October 29, at 8:30 am ET CARMIEL, Israel, October 29, 2020 – Protali |
|
| October 23, 2020 |
Submission of Matters to a Vote of Security Holders - 8-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 8, 2020 (June 7, 2020) Protalix BioTherapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33357 65-0643773 (State or other jurisdiction of incor |
|
| October 1, 2020 |
EX-1.1 2 tm2032084d1ex1-1.htm EXHIBIT 1.1 Exhibit 1.1 EXECUTION VERSION Protalix BioTherapeutics, Inc. Common Stock ($0.001 par value) ATM EQUITY OFFERINGSM SALES AGREEMENT October 1, 2020 BofA Securities, Inc. One Bryant Park New York, New York 10036 As Agent Ladies and Gentlemen: Protalix BioTherapeutics, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions |
|
| October 1, 2020 |
Prospectus Supplement Filed Pursuant to Rule 424(b)(5) (to Prospectus dated April 12, 2019) Registration No. |
|
| October 1, 2020 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 1, 2020 Protalix BioTherapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33357 65-0643773 (State or other jurisdiction of incorporation) (Com |
|
| September 8, 2020 |
Protalix BioTherapeutics Regains Compliance with NYSE American Continued Listing Standards EX-99.1 2 tm2030354d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Protalix BioTherapeutics Regains Compliance with NYSE American Continued Listing Standards CARMIEL, Israel, September 8, 2020 /PRNewswire/ - Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by i |
|
| September 8, 2020 |
Financial Statements and Exhibits, Other Events - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 8, 2020 Protalix BioTherapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33357 65-0643773 (State or other jurisdiction of incorporation) (C |
|
| August 11, 2020 |
Exhibit 99.1 Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce U.S. Food and Drug Administration Acceptance of Biologics License Application (BLA) for Pegunigalsidase Alfa for the Proposed Treatment of Fabry Disease and Grants Priority Review CARMIEL, Israel, August 11, 2020 /PRNewswire/ - Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company fo |
|
| August 11, 2020 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 11, 2020 Protalix BioTherapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33357 65-0643773 (State or other jurisdiction of incorporation) (Com |
|
| August 10, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 10, 2020 Protalix BioTherapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33357 65-0643773 (State or other jurisdiction of incorporation) (Com |
|
| August 10, 2020 |
Form of Stock Option Agreement (Standard) Exhibit 4.9 OPTION AGREEMENT (STANDARD) This Option Agreement is made as of , (the “Agreement”), by and between PROTALIX BIOTHERAPEUTICS, INC., a corporation incorporated under the laws of the State of Delaware (the “Corporation”), and the following employee of the Corporation (the “Optionee”): NAME: ID: WHEREAS, the Corporation maintains the Amended and Restated Protalix BioTherapeutics, Inc., 20 |
|
| August 10, 2020 |
Exhibit 99.1 Protalix BioTherapeutics Reports Second Quarter 2020 Financial Results and Provides Business Update Announced positive top-line data in its Phase III BRIDGE study of PRX-102 for the Treatment of Fabry disease Submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration for PRX-102 for the treatment of Fabry disease Conference call and live webcast sched |
|
| August 10, 2020 |
Amended and Restated Pro BioTherapeutics, Inc. 2006 Stock Incentive Plan Exhibit 10.1 PROTALIX BIOTHERAPEUTICS, INC. AMENDED AND RESTATED 2006 STOCK INCENTIVE PLAN (June 7, 2020) 1. Purposes of the Plan. The purposes of this Plan are to attract and retain the best available personnel, to provide additional incentives to Employees, Directors and Consultants and to promote the success of the Company’s business. 2. Definitions. The following definitions shall apply as use |
|
| August 10, 2020 |
Form of Stock Option Agreement (Executives) Exhibit 4.8 OPTION AGREEMENT (EXECUTIVE OFFICERS) This Option Agreement is made as of , (the “Agreement”), by and between PROTALIX BIOTHERAPEUTICS, INC., a corporation incorporated under the laws of the State of Delaware (the “Corporation”), and the following employee of the Corporation (the “Optionee”): NAME: ID: WHEREAS, the Corporation maintains the Amended and Restated Protalix BioTherapeutics |
|
| August 10, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ⌧ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to 001-33357 (Commission file |
|
| June 11, 2020 |
Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT Under THE SECURITIES ACT OF 1933 Protalix BioTherapeutics, Inc. (Exact name of registrant as specified in its Charter) Delaware 65-0643773 (State or other jurisdiction (I.R.S. Employer of incorporation or organization) Identification Number) 2 Snunit Street Science Park P.O |
|
| June 8, 2020 |
Exhibit 99.1 Protalix BioTherapeutics Appoints Yael Hayon, Ph.D. as its New Vice President, Research and Development CARMIEL, Israel, June 8, 2020 /PRNewswire/ - Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX) today announced the appointment of Yael Hayon, Ph.D. as the Company’s new Vice President, Research and Development, effective July 5, 2020. On June 2, 2020, Yoseph Shaaltiel, P |
|
| June 8, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 8, 2020 (June 7, 2020) Protalix BioTherapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33357 65-0643773 (State or other jurisdiction of incorpo |
|
| June 8, 2020 |
Amended and Restated Employment Agreement with Einat Brill Almon, Ph.D., dated June 7, 2020 Exhibit 10.2 AMENDED & RESTATED EMPLOYMENT AGREEMENT This AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this “Agreement”) is made effective as of June 7, 2020 (the “Effective Date”), by and between Protalix Ltd., a company organized under the laws of the State of Israel (the “Company”) and Einat Brill Almon, Ph.D., a resident of the State of Israel (the “Employee”) (each of the Company and Employee s |
|
| June 8, 2020 |
Employment Agreement with Yael Hayon, Ph.D. dated June 7, 2020 Exhibit 10.1 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (this “Agreement”) is entered into as of June 7, 2020 (the “Effective Date”), by and between Protalix Ltd., a company organized under the laws of the State of Israel (the “Company”) and Dr. Yael Hayon, an Israeli citizen residing in Tel Aviv, Israel (the “Employee”) (each of the Company and Employee shall be referred to herein, as a “Part |
|
| June 1, 2020 |
Quarterly Report - FORM 10-Q/A 10-Q/A 1 tm2014552d310qa.htm FORM 10-Q/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1) (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transiti |
|
| June 1, 2020 |
Exhibit 99.1 Protalix BioTherapeutics Reports First Quarter 2020 Financial Results and Business Update Conference call and live webcast scheduled for Monday, June 1st, 2020 at 8:30 am EDT CARMIEL, Israel, June 1, 2020 /PRNewswire/Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant the |
|
| June 1, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to 001-33357 (Commission file number) PROTALIX |
|
| June 1, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 1, 2020 Protalix BioTherapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33357 65-0643773 (State or other jurisdiction of incorporation) (Commis |
|
| May 28, 2020 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 28, 2020 (May 27, 2020) Protalix BioTherapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33357 65-0643773 (State or other jurisdiction of incorpo |
|
| May 28, 2020 |
Exhibit 99.1 Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Submission of Biologics License Application to U.S. Food and Drug Administration for Pegunigalsidase Alfa for the Treatment of Fabry Disease CARMIEL, Israel, May 28, 2020 /PRNewswire/ - Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development, production and c |
|
| May 11, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 11, 2020 Protalix BioTherapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33357 65-0643773 (State or other jurisdiction of incorporation) (Commis |
|
| May 11, 2020 |
Exhibit 99.1 Protalix BioTherapeutics Announces Positive Topline Results from the BRIDGE Phase III Open-Label, Switch-Over Clinical Trial Evaluating Pegunigalsidase Alfa for the Treatment of Fabry Disease Phase III BRIDGE open-label, switch-over clinical trial met main objectives for safety and efficacy Topline analysis indicates substantial improvement in renal function as measured by mean annual |
|
| May 11, 2020 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 11, 2020 Protalix BioTherapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33357 65-0643773 (State or other jurisdiction of incorporation) (Commis |
|
| April 29, 2020 |
35,208,846 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-237736 PROSPECTUS 35,208,846 Shares of Common Stock This prospectus relates to the offer and sale from time to time by the selling stockholders identified in the section entitled “Selling Stockholders” of up to an aggregate of 35,208,846 shares of our common stock, including 17,604,423 shares held by the selling stockholders and 17,604,423 shar |
|
| April 27, 2020 |
April 27, 2020 VIA EDGAR Jeffrey Gabor Office of Life Sciences U.S. Securities and Exchange Commission Division of Corporation Finance Mail Stop 4720 100 F Street, N.E. Washington, D.C. 20549 Re: Protalix BioTherapeutics, Inc. Registration Statement on Form S-3 Filed April 17, 2020 File No. 333-237736 Dear Mr. McCann: We refer to the registration statement on Form S-3 (File No. 333-237736) (the “R |
|
| April 17, 2020 |
PLX / Protalix BioTherapeutics, Inc. S-3 - - FORM S-3 As filed with the Securities and Exchange Commission on April 17, 2020 Registration No. |
|
| April 15, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
